FDA Issues Complete Response Letter for RISPERDAL CONSTA for … - Businesswire.com
CAMBRIDGE, Mass.–( BUSINESS WIRE )–Alkermes, Inc. (NASDAQ: ALKS) today announced that the Food and Drug Administration (FDA) has asked Alkermes partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), for additional …